title: Ten-year clinical follow-up after sirolimus-eluting stent implantation.
abstract: BACKGROUND
  Little is known on the "very" long-term incidence of major adverse cardiac events (MACE), target-lesion revascularization (TLR), target-vessel revascularization and stent thrombosis after sirolimus-eluting stent (SES) implantation. We present the first study to provide a 10-year clinical follow-up in an unselected patient population who underwent SES implantation.
  
  
  RESULTS
  We ran a systematic 10-year clinical follow-up in a series of 200 consecutive patients treated with unrestricted SES implantation between April 2002 and April 2003 in two Swiss hospitals. Outcomes and follow-up were obtained in all 200 patients. The cumulative 10-year MACE rate was 47% with all-cause death of 20%, cardiac death of 9%, myocardial infarction of 7%, TLR and target-vessel revascularization of 8% and 11% respectively. Academic Research Consortium-defined "definite and probable" stent thrombosis-rate was 2.5%. TLR risk was maximal between 3 to 6 years. New lesion revascularization increased throughout the study period.
  
  
  CONCLUSIONS
  Incidence of TLR was maximal 3 to 6 years after SES implantation and decreased thereafter. MACE and non-TLR revascularization rates steadily increased during the complete follow-up underlining the progression of coronary artery disease.
authors.affiliation: University and Hospital, Fribourg, Switzerland.
authors.forename: Nuno
authors.initials: N
authors.lastname: Palhais
authors.affiliation: University and Hospital, Fribourg, Switzerland.
authors.forename: Diego
authors.initials: D
authors.lastname: Arroyo
authors.affiliation: University and Hospital, Fribourg, Switzerland.
authors.forename: Sonja
authors.initials: S
authors.lastname: Lehmann
authors.affiliation: University and Hospital, Fribourg, Switzerland.
authors.forename: Mario
authors.initials: M
authors.lastname: Togni
authors.affiliation: University and Hospital, Fribourg, Switzerland.
authors.forename: Urs
authors.initials: U
authors.lastname: Kaufmann
authors.affiliation: University and Hospital, Fribourg, Switzerland.
authors.forename: Serban-Georges
authors.initials: SG
authors.lastname: Puricel
authors.affiliation: University and Hospital, Fribourg, Switzerland.
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Stauffer
authors.affiliation: University and Hospital, Fribourg, Switzerland.
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Goy
authors.affiliation: University and Hospital, Fribourg, Switzerland. Electronic address: stephane.cook@unifr.ch.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Cook
mesh_terms: D000368:Aged; D003131:Combined Modality Therapy; D003324:Coronary Artery Disease / Q000628:therapy*; D023903:Coronary Restenosis; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000517:prevention & control*; D009204:Myocardial Revascularization / Q000706:statistics & numerical data; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011446:Prospective Studies; D011475:Prosthesis Failure; D020123:Sirolimus; D013927:Thrombosis; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D020123:Sirolimus